News & Analysis as of

Cancer

Maynard Nexsen

Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 225: Cancer Care Access & Treatments with Dr. Sengar of...

Maynard Nexsen on

Join hosts Heather, Lauren, and John as they sit down with Dr. Sengar, an accomplished oncologist from Alabama Cancer Care, a network committed to delivering quality cancer care to underserved communities. In this episode, we...more

Marshall Dennehey

Right to Subrogation for Medical Bill Payments Not Waived by Failing to Properly Preserve Issue at All Stages of Litigation,...

Marshall Dennehey on

City of Philadelphia v. Wayne Deloatch and Independence Blue Cross (WCAB); Independence Blue Cross v. City of Philadelphia and Wayne Deloatch (WCAB); No. 541 C.D. 2022 and No. 589 C.D. 2022; Filed Dec. 24, 2024 - Wayne...more

Marshall Dennehey

Claimant’s Conversation With Fellow Firefighter About Act 46 Cancer Presumption Was Not the Date He Became Aware of His Cancer’s...

Marshall Dennehey on

West Conshohocken Borough v. David Markland (WCAB); No. 1382 C.D. 2022; filed Jan. 2, 2025 - This case involved a Claim Petition filed based on an occupational disease. The claimant worked as a firefighter and filed an Act 46...more

Mayer Brown

Regulatory and Legal Implications of the Surgeon General’s Call For Cancer Warning On Alcohol Labels

Mayer Brown on

On January 3, 2025, outgoing US Surgeon General Dr. Vivek Murthy released a new advisory outlining the alleged causal link between alcohol consumption and cancer, claiming “numerous high-quality observational studies and...more

Hissey, Mulderig & Friend, PLLC

U.S. Navy Veterans With Cancer from AFFF May Qualify to File a Lawsuit

Veterans of the U.S. Navy who were exposed to Aqueous Film Forming Foam (AFFF) and diagnosed with kidney cancer, pancreatic cancer, testicular cancer, or other types of cancers may be eligible to file a lawsuit and receive...more

Foster Garvey PC

FDA Revoking Authorization for Use of Red No. 3 in Food and Ingested Drugs

Foster Garvey PC on

On January 15, 2025, the Food and Drug Administration (FDA) amended its color additive regulations by revoking its authorization for use in food and ingested medications of FD&C Red No. 3 (Red No. 3), a synthetic red dye....more

Marshall Dennehey

Claimant’s Evidence Satisfied the Three-prong Test to Support the Section 301(F) Presumption That a Firefighter’s Chronic Myeloid...

Marshall Dennehey on

Borough of Hollidaysburg v. Paul Detwiler (WCAB); No. 739 C.D. 2023; Filed November 19, 2024; Judge Wolf - The claimant was a firefighter who developed chronic myeloid leukemia that was diagnosed in 2014. He learned his...more

K&L Gates LLP

FDA Revokes Authorization for the Use of Red Dye No. 3 in Food and Ingestible Drugs

K&L Gates LLP on

On 15 January 2025, the US Food and Drug Administration (FDA) announced that it will revoke the color additive authorization for use of FD&C Red No. 3 in food (including dietary supplements) and ingestible drugs. This ban...more

DLA Piper

FDA Bans Red Dye No. 3 Under the Delaney Clause

DLA Piper on

The US Food and Drug Administration (FDA) has revoked its authorization for the use of FD&C Red No. 3, also known as Red Dye No. 3. Issued on January 15, 2025, the ban will go into effect for food (including dietary...more

ArentFox Schiff

US Surgeon General Advises on Link Between Alcohol and Cancer, Recommends Cancer Warnings on Alcohol Labels; Alcohol Beverage...

ArentFox Schiff on

On January 3, the US Surgeon General issued an advisory on the association between alcohol and the risk of cancer. The alcohol beverage industry has swiftly responded highlighting conflicting studies and federal guidelines....more

Patrick Malone & Associates P.C. | DC Injury...

Better Health Care Newsletter - January 2025

New Year’s is receding fast in the rearview mirror. And for many of us, our sincere resolutions about losing weight and getting fitter are also fading fast. But there’s good news for helping us renew our commitment to...more

Searcy Denney Scarola Barnhart & Shipley

The Link Between Certain Medications and Cancer Risk

When you take a medication your doctor prescribes, the last thing you expect is for it to do more harm than good. But, unfortunately, medications are not always as safe as they should be. In fact, some medications have been...more

Hissey, Mulderig & Friend, PLLC

Roundup Users With Lymphoma May Qualify to File a Lawsuit

Exposure to the weedkiller Roundup (glyphosate) has been linked to an increased risk of non-Hodgkin's lymphoma....more

Goodwin

FDA Approves New Biologic Cancer Treatments

Goodwin on

On November 20th, Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC...more

Allen Matkins

California Environmental Law & Policy Update 12.13.24

Allen Matkins on

The U.S. Environmental Protection Agency (EPA) on Monday banned two solvents found in everyday products that can cause cancer and other serious diseases. It was a move long sought by environmental and health advocates, even...more

Foley & Lardner LLP

Antibody Drug Conjugates Keep Growing: What You Need to Know

Foley & Lardner LLP on

What Are ADCs and Why Are They Growing? Over the past few years economic headwinds have resulted in fewer deals, with companies and private equity firms alike reassessing where to spend money. But one portion of the...more

Maynard Nexsen

Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 214: Pharma Manufacturing in North Carolina with Ed...

Maynard Nexsen on

Recorded at NC Life Sciences Organization’s Annual Meeting, Heather and Matthew welcome Ed Hernandez, who oversees drug product manufacturing at Eli Lilly, an international pharmaceutical company. Ed discusses how Eli Lilly...more

Foley & Lardner LLP

Cancer Drugs: Clinical Trial Issues for Antibody Drug Conjugates (ADCs)/Antibody Therapeutics

Foley & Lardner LLP on

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such as cancer cells, while...more

Stotler Hayes Group, LLC

Balancing Lawyering and Caregiving in the Sandwich Generation - A Woman’s Perspective Part III: Breast Cancer & Stoicism

October is Breast Cancer Awareness Month. In 2024, an estimated 310,720 women will receive an invasive breast cancer diagnosis in the U.S., and 16% will be in women younger than 50 years of age. See Breast Cancer Facts and...more

Nelson Mullins Riley & Scarborough LLP

IARC Releases Its Priority Evaluation List for 2025-2029

The International Agency for Research on Cancer (IARC) released its 2025-2029 Priority List for evaluation in April of this year, see Advisory Group Recommendations on Priorities for the IARC Monographs, The Lancet Oncology...more

Nelson Mullins Riley & Scarborough LLP

IARC Plans Evaluation of Automotive Gasoline and Oxygenated Additives in Early 2025

The International Agency for Research on Cancer (IARC) announced that it will be evaluating “automotive gasoline and some oxygenated additives” between February and March 2025 per IARC Monographs – Volume 138.  The additives...more

Goldberg Segalla

Motion for Summary Judgment Denied as Defendant Failed to Prove Lack of Causation

Goldberg Segalla on

Jurisdiction: Supreme Court of New York, New York County - Plaintiff John P. Reeves alleges asbestos exposure from, among other things, the asbestos-containing caulk of defendant DAP Inc. while serving in the U.S. Navy aboard...more

Goldberg Segalla

Court Denies Motions for Summary Judgment for Valve and Pump Manufacturers

Goldberg Segalla on

Jurisdiction: Supreme Court of New York, New York County - Plaintiff Robert L. Toth worked at various Consolidated Edison powerhouses from 1961 to 1991 as a sheet metal worker. He was diagnosed with lung cancer in 2019 and he...more

Sheppard Mullin Richter & Hampton LLP

Krazati Untitled Letter: A Cautionary Tale for CFL Promotion of Accelerated Approval Drugs

On August 1, 2024, the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) issued an untitled letter to Mirati Therapeutics Inc., a Bristol Myers Squibb Co. (Mirati), relating to promotional...more

Integral Consulting Inc.

Consumer Use of Cosmetic Talc Is Not Related to the Development of Asbestos-Related Disease

The potential causative relationship between exposure to cosmetic talc and asbestos-related disease is of particular interest considering recent, high-visibility cases being litigated across the United States. Talc is a...more

471 Results
 / 
View per page
Page: of 19

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide